Spravato Archives -

NHS patients with treatment-resistant depression in Scotland will be able to access Johnson & Johnson’s Spravato, a drug

After a nay from NICE, Scotland says aye to J&J’s Spravato

https://pharmaphorum.com/news/after-a-nay-from-nice-scotland-says-aye-to-jjs-spravato/

NICE has rejected regular NHS funding for Janssen’s depression spray Spravato (esketamine) for a second time, although the

NICE rejects Janssen’s depression spray Spravato for second time

https://pharmaphorum.com/news/nice-rejects/

The UK healthcare cost-effectiveness agency has said it will not recommend funding for Johnson & Johnson’s antidepressant nasal

NICE rejects J&J’s Spravato for treatment-resistant depression

https://pharmaphorum.com/news/nice-rejects-jjs-spravato-for-treatment-resistant-depression/

Johnson & Johnson has filed for US approval for a new claim on the label for its nasal

J&J seeks wider use of its Spravato antidepressant in US

https://pharmaphorum.com/news/jj-seeks-wider-use-of-its-spravato-antidepressant-in-us/

The FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment

FDA approves Janssen’s ketamine-based nasal antidepressant

https://pharmaphorum.com/news/fda-approves-janssens-ketamine-based-nasal-antidepressant/

Spravato